Minerva Surgical, Inc. (UTRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
UTRS Stock Summary
- UTRS's went public 1.43 years ago, making it older than only 1.72% of listed US stocks we're tracking.
- Over the past twelve months, UTRS has reported earnings growth of 250.58%, putting it ahead of 94.05% of US stocks in our set.
- The volatility of MINERVA SURGICAL INC's share price is greater than that of 98.32% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to MINERVA SURGICAL INC are APYX, MLSS, CDXC, PLAG, and STIM.
- To dig deeper into the stock's financial statements, go to UTRS's page on browse-edgar?action=getcompany&CIK=0001452965.
UTRS Valuation Summary
- UTRS's EV/EBIT ratio is -1.7; this is 108.9% lower than that of the median Technology stock.
- Over the past 17 months, UTRS's price/earnings ratio has gone up 13.7.
Below are key valuation metrics over time for UTRS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| UTRS | 2023-03-21 | 0.1 | 0.3 | -0.4 | -1.7 |
| UTRS | 2023-03-20 | 0.1 | 0.3 | -0.4 | -1.8 |
| UTRS | 2023-03-17 | 0.1 | 0.3 | -0.4 | -1.7 |
| UTRS | 2023-03-16 | 0.1 | 0.3 | -0.4 | -1.7 |
| UTRS | 2023-03-15 | 0.1 | 0.3 | -0.4 | -1.7 |
| UTRS | 2023-03-14 | 0.1 | 0.3 | -0.4 | -1.7 |
UTRS Stock Price Chart Interactive Chart >
UTRS Price/Volume Stats
| Current price | $0.20 | 52-week high | $4.80 |
| Prev. close | $0.21 | 52-week low | $0.15 |
| Day low | $0.19 | Volume | 131,100 |
| Day high | $0.22 | Avg. volume | 1,363,383 |
| 50-day MA | $0.33 | Dividend yield | N/A |
| 200-day MA | $0.96 | Market Cap | 5.97M |
Minerva Surgical, Inc. (UTRS) Company Bio
Minerva Surgical Inc., a commercial-stage medical technology company, focuses on developing, manufacturing, and commercializing minimally invasive solutions to meet the uterine healthcare needs of women. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists across various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Latest UTRS News From Around the Web
Below are the latest news stories about MINERVA SURGICAL INC that investors may wish to consider to help them evaluate UTRS as an investment opportunity.
Minerva Surgical, Inc. (NASDAQ:UTRS) Q4 2022 Earnings Call TranscriptMinerva Surgical, Inc. (NASDAQ:UTRS) Q4 2022 Earnings Call Transcript March 21, 2023 Operator: Thank you for standing by, and welcome to Minerva’s Fourth Quarter and Full Year 2022 Earnings Call. At this time, all participants are in a listen-only mode. After this speakers’ presentation, there will be a question-and-answer session. I would now like to […] |
Q4 2022 Minerva Surgical Inc Earnings CallQ4 2022 Minerva Surgical Inc Earnings Call |
Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial OfficerSANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, announced today the appointment of Kaile Zagger as its new Chief Commercial Officer. Ms. Zagger’s leadership will help guide the strategic growth of the company and advance its position as a leader in women’s healthcare solutions. “We are excited to have Kaile as our new Chief Commer |
Minerva Surgical Reports Fourth Quarter and Full-Year 2022 Financial ResultsSANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a woman's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported fourth quarter and full-year financial results for the period ended December 31, 2022. Fourth Quarter and Recent Business Highlights: Reported revenue of $13.8 million in the fourth quarter of 2022, compared with revenue of $13.6 million in the fourth qu |
Minerva Surgical to Announce Fourth Quarter and Full Year 2022 Financial ResultsSANTA CLARA, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS), a woman’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21, 2023. In conjunction with the release, the company will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlight |
UTRS Price Returns
| 1-mo | -41.18% |
| 3-mo | -16.28% |
| 6-mo | -74.86% |
| 1-year | -95.65% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -10.47% |
| 2022 | -95.65% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...